Oncocross Signs Three-Way Agreement with April Bio and OmicsAI for Joint New Drug Development
Predicted impact: Low
Three-way joint drug development agreement; no financial terms disclosed.
397030 · KOSDAQ · ₩397030 · 에이프릴바이오
Predicted impact: Low
Three-way joint drug development agreement; no financial terms disclosed.
Also known as: AprilBio / 에이프릴바이오 / 397030 / KRX:397030
Source: KRX statistical information